Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study

Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in verruca vulgaris. Aim of the work: To assess the expression of involucrin in verrucae vulgaris before and after injection of vitamin D3. Subjects and Methods: This study included 60 patients with verrucae vulgaris subjected to intralesional injection of vitamin D3 at three weeks interval for a maximum of five sessions. Immunohistochemical assessment of involucrin was done before and after injection and compared to skin biopsies from 30 healthy individuals

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Verruca Vulgaris DNA Virus Infections Infections Involucrin Papillomavirus Infections Skin Diseases Skin Diseases, Infectious Skin Diseases, Viral Skin and Connective Tissue Diseases Tumor Virus Infections Virus Diseases Warts

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Essam Mohamed El-sayed Akl

Banhā, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with multiple verruca vulgaris Patients with with verrucae vulgaris with size more than 3 cm

Exclusion criteria

Patients with a past history of allergic response to vitamin D. Pregnant or lactating females. Hepatic patients. Renal patients. Patients with bleeding tendency.

Treatment and study plan

Cholecalciferol

Drug

Cholecalciferol injection

Primary outcomes

Resolution of verrucae

Time frame: 3 months

Decrease of verrucae size Decrease of verrucae number

Secondary outcomes

Involucrin expression

Time frame: 3 months

Change of expression pattern of involucrin by immunohistochemical study Change of expression grade of involucrin by immunohistochemical study

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Mar 11, 2021
Registry last updated: Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed